ACI 24

Drug Profile

ACI 24

Alternative Names: ACI-24; Anti-Abeta vaccine - AC immune; Pal1-15 acetate salt

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator AC Immune
  • Developer AC Immune; University of California, San Diego
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 Apr 2016 Phase-Ib clinical trials in Alzheimer's disease in USA, Switzerland (SC)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Jan 2016 AC Immune in collaboration with University of California San Diego plans a phase Ib trial for Alzheimer's disease-like characteristics in Down syndrome in USA and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top